Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS)

Inclusion Criteria: * Patients must have completed 52 weeks of treatment of the double blind placebo-controlled phase of ALS-TAL-201. * Women must be postmenopausal, surgically sterile, or using adequate birth control methods. * Patients must be willing and able to give written informed consent prior to performing any open-label study procedures. Exclusion Criteria: * Patients with ECG signs of Brugada syndrome and/ or complete or incomplete Right Bundle Branch Block * Patients using any of the following: * Chronic use of lithium carbonate * Chronic use of mecasermin (rhIGF-1) * Chronic use of minocycline * Chronic use of more than 600mg/day coenzyme Q10 * Chronic use of any marketed drug, if its use was not clearly indicated for any underlying medical condition other than ALS (symptomatic drugs for ALS and supplements allowed) * Patients participating in any other investigational drug study and use of any other investigational drug * Patients taking drugs that may interact with Talampanel * Females who are pregnant or nursing. * Females of child-bearing potential who do not practice medically acceptable methods of contraception. * Any condition of the patient which the investigator feels may interfere with participation in the study.